Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;49(4):504-510.
doi: 10.1038/ng.3789. Epub 2017 Feb 13.

Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples

Jack A Kosmicki  1   2   3   4   5 , Kaitlin E Samocha  1   2   3   5 , Daniel P Howrigan  1   2   3 , Stephan J Sanders  6 , Kamil Slowikowski  2   4   7   8 , Monkol Lek  1   2 , Konrad J Karczewski  1   2 , David J Cutler  9 , Bernie Devlin  10 , Kathryn Roeder  11 , Joseph D Buxbaum  12   13   14   15   16   17 , Benjamin M Neale  1   2   3 , Daniel G MacArthur  1   2 , Dennis P Wall  18 , Elise B Robinson  1   2   3 , Mark J Daly  1   2   3
Affiliations

Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples

Jack A Kosmicki et al. Nat Genet. 2017 Apr.

Abstract

Recent research has uncovered an important role for de novo variation in neurodevelopmental disorders. Using aggregated data from 9,246 families with autism spectrum disorder, intellectual disability, or developmental delay, we found that ∼1/3 of de novo variants are independently present as standing variation in the Exome Aggregation Consortium's cohort of 60,706 adults, and these de novo variants do not contribute to neurodevelopmental risk. We further used a loss-of-function (LoF)-intolerance metric, pLI, to identify a subset of LoF-intolerant genes containing the observed signal of associated de novo protein-truncating variants (PTVs) in neurodevelopmental disorders. LoF-intolerant genes also carry a modest excess of inherited PTVs, although the strongest de novo-affected genes contribute little to this excess, thus suggesting that the excess of inherited risk resides in lower-penetrant genes. These findings illustrate the importance of population-based reference cohorts for the interpretation of candidate pathogenic variants, even for analyses of complex diseases and de novo variation.

PubMed Disclaimer

Conflict of interest statement

Competing Financial Interests

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Illustration of class 1 and class 2 de novo variants with the genotypes of each variant for 8 of the 60,706 individuals in ExAC.
Figure 2
Figure 2
Properties of class 2 de novo variants. (a) The proportion of de novo variants across each cohort split between class 1 (left) and class 2 (right) with CpG variants marked in black. Class 2 de novo variants are strongly enriched for CpG variants (P < 10−20). The corresponding figure using the non-psychiatric version of ExAC can be found in Supplementary Figure 2. (b) Expected recurrence rate (rate of class 2 de novo variants across ID/DD, ASD, and unaffected ASD siblings) given the sample size of the reference dataset. The red dot indicates the observed recurrence rate of the non-psychiatric version of ExAC. (c) Allele frequency distribution of class 2 de novo CpGs by cohort with the matching distribution of CpG variants in ExAC for comparison. Allele frequency distributions do not significantly differ (P=0.14; Wilcoxon rank sum test). Error bars represent 95% confidence intervals throughout (a) – (c). ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder.
Figure 2
Figure 2
Properties of class 2 de novo variants. (a) The proportion of de novo variants across each cohort split between class 1 (left) and class 2 (right) with CpG variants marked in black. Class 2 de novo variants are strongly enriched for CpG variants (P < 10−20). The corresponding figure using the non-psychiatric version of ExAC can be found in Supplementary Figure 2. (b) Expected recurrence rate (rate of class 2 de novo variants across ID/DD, ASD, and unaffected ASD siblings) given the sample size of the reference dataset. The red dot indicates the observed recurrence rate of the non-psychiatric version of ExAC. (c) Allele frequency distribution of class 2 de novo CpGs by cohort with the matching distribution of CpG variants in ExAC for comparison. Allele frequency distributions do not significantly differ (P=0.14; Wilcoxon rank sum test). Error bars represent 95% confidence intervals throughout (a) – (c). ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder.
Figure 2
Figure 2
Properties of class 2 de novo variants. (a) The proportion of de novo variants across each cohort split between class 1 (left) and class 2 (right) with CpG variants marked in black. Class 2 de novo variants are strongly enriched for CpG variants (P < 10−20). The corresponding figure using the non-psychiatric version of ExAC can be found in Supplementary Figure 2. (b) Expected recurrence rate (rate of class 2 de novo variants across ID/DD, ASD, and unaffected ASD siblings) given the sample size of the reference dataset. The red dot indicates the observed recurrence rate of the non-psychiatric version of ExAC. (c) Allele frequency distribution of class 2 de novo CpGs by cohort with the matching distribution of CpG variants in ExAC for comparison. Allele frequency distributions do not significantly differ (P=0.14; Wilcoxon rank sum test). Error bars represent 95% confidence intervals throughout (a) – (c). ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder.
Figure 3
Figure 3
Partitioning the rate of de novo variants per exome by class 1, class 2, and pLI. Within each grouping, the rate – variants per individual – is shown for ID/DD (left), ASD (middle), and unaffected ASD siblings (right) with the number of individuals labeled in the legends. (a) Rate of de novo synonymous variants per exome partitioned into class 2 (middle) and class 1 (right). No significant difference was observed for any grouping of de novo synonymous variants. (b) Rate of de novo PTVs per exome partitioned into class 2 (middle) and class 1 (right). Only class 1 de novo PTVs in ID/DD and ASD show association when compared to unaffected ASD siblings. (c) Rate of class 2 de novo PTVs broken by different ExAC global allele frequency (AF) thresholds: singleton (observed once; left), AF < 0.0001 (middle), and AF < 0.001 (right). (d) Rate of class 1 de novo PTVs partitioned into class 1 de novo PTVs in pLI ≥ 0.9 genes (right), and class 1 de novo PTVs in pLI < 0.9 genes (middle). The entire observed association for de novo PTVs resides in class 1 de novo PTVs in pLI ≥ 0.9 genes. For all such analyses, the rate ratio and significance were calculated by comparing the rate for ID/DD and ASD to the rate in unaffected ASD siblings using a two-sided Poisson exact test for synonymous variants and one-sided for the remainder (Online Methods). Error bars represent 95% confidence intervals throughout (a) – (d). See Supplementary Fig. 3 for the corresponding figures using the non-psychiatric version of ExAC. ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance; NS, not significant.
Figure 3
Figure 3
Partitioning the rate of de novo variants per exome by class 1, class 2, and pLI. Within each grouping, the rate – variants per individual – is shown for ID/DD (left), ASD (middle), and unaffected ASD siblings (right) with the number of individuals labeled in the legends. (a) Rate of de novo synonymous variants per exome partitioned into class 2 (middle) and class 1 (right). No significant difference was observed for any grouping of de novo synonymous variants. (b) Rate of de novo PTVs per exome partitioned into class 2 (middle) and class 1 (right). Only class 1 de novo PTVs in ID/DD and ASD show association when compared to unaffected ASD siblings. (c) Rate of class 2 de novo PTVs broken by different ExAC global allele frequency (AF) thresholds: singleton (observed once; left), AF < 0.0001 (middle), and AF < 0.001 (right). (d) Rate of class 1 de novo PTVs partitioned into class 1 de novo PTVs in pLI ≥ 0.9 genes (right), and class 1 de novo PTVs in pLI < 0.9 genes (middle). The entire observed association for de novo PTVs resides in class 1 de novo PTVs in pLI ≥ 0.9 genes. For all such analyses, the rate ratio and significance were calculated by comparing the rate for ID/DD and ASD to the rate in unaffected ASD siblings using a two-sided Poisson exact test for synonymous variants and one-sided for the remainder (Online Methods). Error bars represent 95% confidence intervals throughout (a) – (d). See Supplementary Fig. 3 for the corresponding figures using the non-psychiatric version of ExAC. ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance; NS, not significant.
Figure 3
Figure 3
Partitioning the rate of de novo variants per exome by class 1, class 2, and pLI. Within each grouping, the rate – variants per individual – is shown for ID/DD (left), ASD (middle), and unaffected ASD siblings (right) with the number of individuals labeled in the legends. (a) Rate of de novo synonymous variants per exome partitioned into class 2 (middle) and class 1 (right). No significant difference was observed for any grouping of de novo synonymous variants. (b) Rate of de novo PTVs per exome partitioned into class 2 (middle) and class 1 (right). Only class 1 de novo PTVs in ID/DD and ASD show association when compared to unaffected ASD siblings. (c) Rate of class 2 de novo PTVs broken by different ExAC global allele frequency (AF) thresholds: singleton (observed once; left), AF < 0.0001 (middle), and AF < 0.001 (right). (d) Rate of class 1 de novo PTVs partitioned into class 1 de novo PTVs in pLI ≥ 0.9 genes (right), and class 1 de novo PTVs in pLI < 0.9 genes (middle). The entire observed association for de novo PTVs resides in class 1 de novo PTVs in pLI ≥ 0.9 genes. For all such analyses, the rate ratio and significance were calculated by comparing the rate for ID/DD and ASD to the rate in unaffected ASD siblings using a two-sided Poisson exact test for synonymous variants and one-sided for the remainder (Online Methods). Error bars represent 95% confidence intervals throughout (a) – (d). See Supplementary Fig. 3 for the corresponding figures using the non-psychiatric version of ExAC. ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance; NS, not significant.
Figure 3
Figure 3
Partitioning the rate of de novo variants per exome by class 1, class 2, and pLI. Within each grouping, the rate – variants per individual – is shown for ID/DD (left), ASD (middle), and unaffected ASD siblings (right) with the number of individuals labeled in the legends. (a) Rate of de novo synonymous variants per exome partitioned into class 2 (middle) and class 1 (right). No significant difference was observed for any grouping of de novo synonymous variants. (b) Rate of de novo PTVs per exome partitioned into class 2 (middle) and class 1 (right). Only class 1 de novo PTVs in ID/DD and ASD show association when compared to unaffected ASD siblings. (c) Rate of class 2 de novo PTVs broken by different ExAC global allele frequency (AF) thresholds: singleton (observed once; left), AF < 0.0001 (middle), and AF < 0.001 (right). (d) Rate of class 1 de novo PTVs partitioned into class 1 de novo PTVs in pLI ≥ 0.9 genes (right), and class 1 de novo PTVs in pLI < 0.9 genes (middle). The entire observed association for de novo PTVs resides in class 1 de novo PTVs in pLI ≥ 0.9 genes. For all such analyses, the rate ratio and significance were calculated by comparing the rate for ID/DD and ASD to the rate in unaffected ASD siblings using a two-sided Poisson exact test for synonymous variants and one-sided for the remainder (Online Methods). Error bars represent 95% confidence intervals throughout (a) – (d). See Supplementary Fig. 3 for the corresponding figures using the non-psychiatric version of ExAC. ID/DD, intellectual disability / developmental delay; ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance; NS, not significant.
Figure 4
Figure 4
Phenotypic associations for ASD de novo PTVs. (a) IQ distribution of class 1 de novo PTVs in pLI ≥ 0.9 genes (red) and remaining de novo PTVs (class 2 and class 1 pLI < 0.9; grey) in 393 individuals with ASD with a measured full-scale IQ. Dots indicate the rate in unaffected ASD siblings for their respective categories of de novo PTVs. P-values calculated using Poisson regression. Only class 1 de novo PTVs show association with full-scale IQ. (b) Rate of class 1 de novo PTVs (left set) and the remaining de novo PTVs (class 2 & class 1 in LoF-tolerant genes, right set) in ID/DD (left two bars) and ASD (middle four bars) split by sex and ID with the number of individuals labeled in the legends. Error bars represent 95% confidence intervals, and P-values were calculated using one-side Poisson exact tests comparing to unaffected ASD siblings. ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance.
Figure 4
Figure 4
Phenotypic associations for ASD de novo PTVs. (a) IQ distribution of class 1 de novo PTVs in pLI ≥ 0.9 genes (red) and remaining de novo PTVs (class 2 and class 1 pLI < 0.9; grey) in 393 individuals with ASD with a measured full-scale IQ. Dots indicate the rate in unaffected ASD siblings for their respective categories of de novo PTVs. P-values calculated using Poisson regression. Only class 1 de novo PTVs show association with full-scale IQ. (b) Rate of class 1 de novo PTVs (left set) and the remaining de novo PTVs (class 2 & class 1 in LoF-tolerant genes, right set) in ID/DD (left two bars) and ASD (middle four bars) split by sex and ID with the number of individuals labeled in the legends. Error bars represent 95% confidence intervals, and P-values were calculated using one-side Poisson exact tests comparing to unaffected ASD siblings. ASD, autism spectrum disorder; PTV, protein truncating variant; pLI, probability of loss-of-function intolerance.
See this image and copyright information in PMC

Similar articles

  • Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders.
    Reuter MS, Tawamie H, Buchert R, Hosny Gebril O, Froukh T, Thiel C, Uebe S, Ekici AB, Krumbiegel M, Zweier C, Hoyer J, Eberlein K, Bauer J, Scheller U, Strom TM, Hoffjan S, Abdelraouf ER, Meguid NA, Abboud A, Al Khateeb MA, Fakher M, Hamdan S, Ismael A, Muhammad S, Abdallah E, Sticht H, Wieczorek D, Reis A, Abou Jamra R. Reuter MS, et al. JAMA Psychiatry. 2017 Mar 1;74(3):293-299. doi: 10.1001/jamapsychiatry.2016.3798. JAMA Psychiatry. 2017. PMID: 28097321
  • De novo variants in neurodevelopmental disorders-experiences from a tertiary care center.
    Brunet T, Jech R, Brugger M, Kovacs R, Alhaddad B, Leszinski G, Riedhammer KM, Westphal DS, Mahle I, Mayerhanser K, Skorvanek M, Weber S, Graf E, Berutti R, Necpál J, Havránková P, Pavelekova P, Hempel M, Kotzaeridou U, Hoffmann GF, Leiz S, Makowski C, Roser T, Schroeder SA, Steinfeld R, Strobl-Wildemann G, Hoefele J, Borggraefe I, Distelmaier F, Strom TM, Winkelmann J, Meitinger T, Zech M, Wagner M. Brunet T, et al. Clin Genet. 2021 Jul;100(1):14-28. doi: 10.1111/cge.13946. Epub 2021 Mar 1. Clin Genet. 2021. PMID: 33619735
  • De novo variants in neurodevelopmental disorders with epilepsy.
    Heyne HO, Singh T, Stamberger H, Abou Jamra R, Caglayan H, Craiu D, De Jonghe P, Guerrini R, Helbig KL, Koeleman BPC, Kosmicki JA, Linnankivi T, May P, Muhle H, Møller RS, Neubauer BA, Palotie A, Pendziwiat M, Striano P, Tang S, Wu S; EuroEPINOMICS RES Consortium; Poduri A, Weber YG, Weckhuysen S, Sisodiya SM, Daly MJ, Helbig I, Lal D, Lemke JR. Heyne HO, et al. Nat Genet. 2018 Jul;50(7):1048-1053. doi: 10.1038/s41588-018-0143-7. Epub 2018 Jun 25. Nat Genet. 2018. PMID: 29942082
  • Estimating contribution of rare non-coding variants to neuropsychiatric disorders.
    Takata A. Takata A. Psychiatry Clin Neurosci. 2019 Jan;73(1):2-10. doi: 10.1111/pcn.12774. Epub 2018 Oct 6. Psychiatry Clin Neurosci. 2019. PMID: 30293238 Review.
  • Human GRIN2B variants in neurodevelopmental disorders.
    Hu C, Chen W, Myers SJ, Yuan H, Traynelis SF. Hu C, et al. J Pharmacol Sci. 2016 Oct;132(2):115-121. doi: 10.1016/j.jphs.2016.10.002. Epub 2016 Oct 19. J Pharmacol Sci. 2016. PMID: 27818011 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Developmental D.M.N.S.Y. & Investigators P. Morbidity mortality weekly report. Surveillance summaries. Vol. 63. Washington, DC: 2014. Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network 11 sites, United States, 2010; p. 1. 2002. - PubMed
    1. Lee SH, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984–94. - PMC - PubMed
    1. Gaugler T, et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014;46:881–5. - PMC - PubMed
    1. Klei L, et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism. 2012;3:9. - PMC - PubMed
    1. De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–215. - PMC - PubMed

MeSH terms